Key Insights

Highlights

Treatment Research

1 treatments under study, led by Telmisartan

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Terminated1

Clinical Trials (1)

Research Network

Common Treatments

  • Telmisartan1

Active Sponsors

  • CTCA1
  • Heidelberg University1
  • RWTH Aachen University1
  • Bayer1

Top Investigators

Related Conditions

  • Arterial Hypertension1

Activity Timeline